Management of Hemorrhagic Cavernoma

Initial Assessment and Risk Stratification

The American Academy of Neurology recommends MRI with T2-weighted gradient-echo or susceptibility-weighted imaging (SWI) to identify the hemorrhagic cavernoma, assess hemorrhage age, detect additional lesions, and evaluate the hemosiderin rim 2, 3
Evaluate for associated developmental venous anomalies (DVAs), present in approximately 20% of cases, as hemorrhage is typically attributed to the cavernoma rather than the DVA itself 2, 3
Deeply situated cavernomas (basal ganglia, thalamus, brainstem) carry higher baseline hemorrhage risk and surgical morbidity compared to superficial lesions 2, 4

The American Heart Association recommends surgical resection for symptomatic hemorrhagic cavernomas in non-eloquent locations, particularly if causing medically refractory seizures or progressive neurological deficits 2
Stereotactic radiosurgery with marginal doses of 11-13 Gy (single fraction) is recommended for surgically inaccessible or high-risk hemorrhagic cavernomas 1
SRS reduces annual hemorrhage risk and provides seizure control in 59.6% achieving Engel class I or II 1

Anticoagulation is NOT absolutely contraindicated in hemorrhagic cavernomas unless active major bleeding, recent intracranial hemorrhage, or severe thrombocytopenia (<50,000/mL) is present 4
The American College of Cardiology recommends therapeutic anticoagulation (INR 2.0-3.0) for superficial lesions (temporal, cerebellar) with strong anticoagulation indications (cardioembolic stroke prevention, acute VTE, high-risk cardiac conditions) 4

Do not rely solely on standard MRI sequences—gradient-echo or SWI sequences are essential for detecting multiple lesions and smaller cavernomas 3
Avoid unnecessary surgical intervention in asymptomatic elderly patients as treatment risks outweigh potential benefits given shorter life expectancy 2
Do not include the hemosiderin rim in radiosurgery treatment planning as it potentiates radiation effects 1, 3